Cargando…

Cannabinoid-Based Ocular Therapies and Formulations

The interest in the pharmacological applications of cannabinoids is largely increasing in a wide range of medical areas. Recently, research on its potential role in eye conditions, many of which are chronic and/or disabling and in need of new alternative treatments, has intensified. However, due to...

Descripción completa

Detalles Bibliográficos
Autores principales: Saraiva, Sofia M., Martín-Banderas, Lucía, Durán-Lobato, Matilde
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10146987/
https://www.ncbi.nlm.nih.gov/pubmed/37111563
http://dx.doi.org/10.3390/pharmaceutics15041077
_version_ 1785034708453687296
author Saraiva, Sofia M.
Martín-Banderas, Lucía
Durán-Lobato, Matilde
author_facet Saraiva, Sofia M.
Martín-Banderas, Lucía
Durán-Lobato, Matilde
author_sort Saraiva, Sofia M.
collection PubMed
description The interest in the pharmacological applications of cannabinoids is largely increasing in a wide range of medical areas. Recently, research on its potential role in eye conditions, many of which are chronic and/or disabling and in need of new alternative treatments, has intensified. However, due to cannabinoids’ unfavorable physicochemical properties and adverse systemic effects, along with ocular biological barriers to local drug administration, drug delivery systems are needed. Hence, this review focused on the following: (i) identifying eye disease conditions potentially subject to treatment with cannabinoids and their pharmacological role, with emphasis on glaucoma, uveitis, diabetic retinopathy, keratitis and the prevention of Pseudomonas aeruginosa infections; (ii) reviewing the physicochemical properties of formulations that must be controlled and/or optimized for successful ocular administration; (iii) analyzing works evaluating cannabinoid-based formulations for ocular administration, with emphasis on results and limitations; and (iv) identifying alternative cannabinoid-based formulations that could potentially be useful for ocular administration strategies. Finally, an overview of the current advances and limitations in the field, the technological challenges to overcome and the prospective further developments, is provided.
format Online
Article
Text
id pubmed-10146987
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-101469872023-04-29 Cannabinoid-Based Ocular Therapies and Formulations Saraiva, Sofia M. Martín-Banderas, Lucía Durán-Lobato, Matilde Pharmaceutics Review The interest in the pharmacological applications of cannabinoids is largely increasing in a wide range of medical areas. Recently, research on its potential role in eye conditions, many of which are chronic and/or disabling and in need of new alternative treatments, has intensified. However, due to cannabinoids’ unfavorable physicochemical properties and adverse systemic effects, along with ocular biological barriers to local drug administration, drug delivery systems are needed. Hence, this review focused on the following: (i) identifying eye disease conditions potentially subject to treatment with cannabinoids and their pharmacological role, with emphasis on glaucoma, uveitis, diabetic retinopathy, keratitis and the prevention of Pseudomonas aeruginosa infections; (ii) reviewing the physicochemical properties of formulations that must be controlled and/or optimized for successful ocular administration; (iii) analyzing works evaluating cannabinoid-based formulations for ocular administration, with emphasis on results and limitations; and (iv) identifying alternative cannabinoid-based formulations that could potentially be useful for ocular administration strategies. Finally, an overview of the current advances and limitations in the field, the technological challenges to overcome and the prospective further developments, is provided. MDPI 2023-03-27 /pmc/articles/PMC10146987/ /pubmed/37111563 http://dx.doi.org/10.3390/pharmaceutics15041077 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Saraiva, Sofia M.
Martín-Banderas, Lucía
Durán-Lobato, Matilde
Cannabinoid-Based Ocular Therapies and Formulations
title Cannabinoid-Based Ocular Therapies and Formulations
title_full Cannabinoid-Based Ocular Therapies and Formulations
title_fullStr Cannabinoid-Based Ocular Therapies and Formulations
title_full_unstemmed Cannabinoid-Based Ocular Therapies and Formulations
title_short Cannabinoid-Based Ocular Therapies and Formulations
title_sort cannabinoid-based ocular therapies and formulations
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10146987/
https://www.ncbi.nlm.nih.gov/pubmed/37111563
http://dx.doi.org/10.3390/pharmaceutics15041077
work_keys_str_mv AT saraivasofiam cannabinoidbasedoculartherapiesandformulations
AT martinbanderaslucia cannabinoidbasedoculartherapiesandformulations
AT duranlobatomatilde cannabinoidbasedoculartherapiesandformulations